Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Novo Nordisk Board Rode a Weight-Loss Wave
Transcript
- Lucas: So a few weeks ago, I was reading the annual report of a company that most people couldn't even name a decade ago, and now it's basically the most valuable company in Europe. I'm talking about Novo Nordisk. Luna: The Ozempic people. Right. Lucas: Exactly. And in this episode, I want to zoom in on the board's role in that transformation. Because it's not just that they had a good drug. It's that the board made a series of bets, starting about ten years ago, that turned a sleepy Danish insulin maker into the center of a global health phenomenon. Luna: What was the big bet? I mean, they've been making insulin forever. What changed? Lucas: The big bet was deciding that obesity is a chronic disease worth treating with medication, not just a lifestyle issue. That seems obvious now, but in 2014, the medical establishment was deeply skeptical. And the board had to approve years of research and clinical trials with no guarantee of success. Luna: So they were early on something that could have flopped. Lucas: Right. And the board had to be comfortable with the risk. They were already a leader in diabetes care, and they could have just stuck to their knitting. Instead, they doubled down on GLP-1 drugs, which were originally developed for diabetes, and started testing them for weight loss. Luna: And that turned into Wegovy. But wasn't there a moment when the board almost walked away? I remember reading about some early trial results that were underwhelming. Lucas: Yeah, there was a phase two trial back in 2016 where the weight loss results were decent but not spectacular. And I think a lot of boards would have looked at that and said, 'we've spent a billion dollars, let's cut our losses.' But the Novo board, led by the chairman at the time, Lars Rebien Sørensen, took a longer view. They saw the potential in the mechanism and the growing obesity epidemic. Luna: So they were thinking about the long tail, not just the next quarter. Lucas: Exactly. And that patient capital is a huge part of the story. But it wasn't just the science. The board also had to think about manufacturing capacity. When Wegovy launched in 2021, demand exploded. They couldn't make enough. And the board had to approve massive capital expenditures, like billions of dollars, to build new factories and expand production. Luna: That's a bet on demand that might not last, especially as competition from Eli Lilly heats up. Lucas: Right. And that's where the board's risk management gets interesting. They had to balance the urgency of meeting patient demand against the risk of overbuilding if the market shifts. But they chose to invest aggressively, and that decision has paid off so far. Their market cap has surged to over five hundred billion dollars. Luna: Five hundred billion. That's bigger than the entire Danish GDP. Lucas: It is, which is a wild thought. But the board isn't just patting itself on the back. They're dealing with a different set of challenges now. There's pricing pressure, for one. Governments and insurers are pushing back on the list price of Wegovy, which is over a thousand dollars a month in the US. Luna: And there's the patent cliff. Those drugs are going to lose exclusivity in the early 2030s, right? Lucas: Yeah, around 2032 for Wegovy in the US. So the board has been thinking about the next act. They've been investing in oral versions, in combination therapies, and even in drugs for other conditions like cardiovascular disease and sleep apnea. It's a pipeline question, and the board has to keep feeding it. Luna: So they're not just riding one wave. They're trying to build a surfboard for the next one. Lucas: Right. And that's a board-level discipline. But there's also a governance question that I find really interesting, and it's about how the board handled the cultural shift inside the company. Novo went from being a family-owned, conservative company to a global superstar. That can breed arrogance or complacency. How do you keep the mission-driven culture intact? Luna: I've read that they have a strong 'patient-first' ethos, baked into their charter or something. Lucas: Yeah, they have an unusual governance structure. The Novo Foundation is the controlling shareholder, and it has a mandate to improve the lives of people with diabetes and other chronic diseases. So the board isn't just maximizing shareholder value. They have a dual mission. And I think that's helped them navigate the criticism about pricing and access. Luna: But they're still charging a thousand dollars a month. How do they reconcile that with a patient-first mission? Lucas: It's a tension, for sure. And the board has been proactive about it. They've expanded patient assistance programs, and they've been transparent about the cost of manufacturing and R&D. But they're also a public company with a fiduciary duty to shareholders. So the board has to walk a line between making a profit and making a difference. Luna: Which brings up the question of what other companies can learn from the Novo playbook. Lucas: I think the biggest lesson is the value of a long-term, patient board. They were willing to fund research for a decade before seeing a return. That's rare. Most boards would have pulled the plug after the first failed trial. But they saw the bigger picture, and they stuck with it. Luna: And they also diversified their bets, not putting all their eggs in one basket. Lucas: Right. They kept a broad pipeline, even while focusing on obesity. And they were also proactive about capacity, which is something a lot of boards overlook. They saw the operational risk and addressed it head-on. Luna: It's a good reminder that a board's job isn't just to say yes or no to big ideas. It's to think about the whole system. Lucas: Exactly. And if that system thinking is useful to you, if these conversations have moved your work forward in some small way, the best way to keep them ad-free is to support the show directly. You can do that at buy me a coffee dot com slash fexingo. It's a small gesture, but it keeps these deep dives coming. Luna: And it really helps. Even a few bucks makes a difference for a small podcast like ours. Lucas: Alright, back to the boardroom. So another thing that strikes me about Novo's board is how they handled the public scrutiny. When Wegovy went viral, there was a lot of debate about whether it was a miracle drug or a vanity drug. And the board had to ensure the company stayed focused on the health outcomes, not just the hype. Luna: How do you do that? I mean, you can't control the narrative entirely. Lucas: No, but you can control your own messaging. Novo's board approved a strategy of publishing clinical trial data, engaging with the medical community, and being upfront about the side effects. They even launched a dedicated website for healthcare providers. It's a way of building trust, which is essential in pharma. Luna: And they also faced pressure from the SEC or something? I recall a subpoena last year. Lucas: Yeah, the SEC was looking into their pricing practices, and Novo said they were cooperating. That kind of regulatory risk is something the board has to monitor closely. But they've navigated it so far, and their stock has remained strong. Luna: So, looking ahead, what's the next big test for the Novo board? Lucas: I'd say it's the challenge of maintaining growth as competition increases and as the media cycle moves on. They're also facing potential reimbursement hurdles in Europe, where some countries are balking at the cost. The board will need to keep innovating and keep the pipeline full. And they'll need to manage the inevitable scrutiny when the patent cliff approaches. Luna: It's a lot of pressure. But if anyone can handle it, it's a board that's been through a decade of hypergrowth. Lucas: True. And I think the key lesson for all of us is that a great board isn't just a collection of smart people. It's a group that can make tough calls, stay focused on the long term, and keep their values intact under pressure. Novo Nordisk's board has done that, and it's worth studying. Luna: Well, I'm glad we finally did an episode on a company that's actually doing something good for the world. Lucas: Ha, well, there's still plenty of controversy. But yeah, it's a fascinating case study in strategic patience. That's all for today. Thanks for listening.